Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Medigene to Present at Upcoming Conferences
07 mai 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
02 mai 2024 04h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
02 mai 2024 02h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
01 mai 2024 06h55 HE
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
EAACI Congress 2024: นวัตกรรมและความก้าวหน้าในการรักษาโรคภูมิแพ้
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
ในระหว่างการประชุมจะมีการนำเสนอเซสชันทางวิทยาศาสตร์มากกว่า 150 ครั้ง โดยมุ่งเน้นที่ความก้าวหน้าทางวิทยาศาสตร์สิ่งแวดล้อม โรคภูมิแพ้อาหาร นวัตกรรมในการใช้ภูมิคุ้มกันบำบัดและโรคภูมิแพ้ในเด็ก และอื่นๆ...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Rawatan Alahan
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Lebih 150 sesi saintifik akan dibentangkan semasa kongres itu, yang antara lainnya memfokuskan kepada kemajuan dalam sains alam sekitar, alahan makanan, inovasi dalam imunoterapi dan alahan...
2024년도 EAACI 학술대회: 알레르기 치료의 혁신과 발전
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
학술대회 일환으로 환경 과학, 식품 알레르기, 면역 치료 혁신, 소아 알레르기 등의 주제에 초점 맞춘 150개 이상의 과학 세션 열릴 예정최대 규모의 알레르기 및 면역학 학술대회에서 다뤄질 정밀 의학, AI, 면역 치료, 면역 조절제5월 31일부터 6월 3일까지 스페인 발렌시아에서 개최 스페인 발렌시아, April 30, 2024 (GLOBE...
2024 年欧洲过敏与临床免疫学会大会：过敏治疗的创新和进步
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
大会期间将举行 150 多场科学会议，重点探讨环境科学、食物过敏、免疫疗法创新和儿科过敏等方面的进展。作为规模最大的过敏和免疫学盛会，本次大会将汇聚精准医学、人工智能、免疫疗法和免疫调节剂等前沿领域。大会将于 5 月 31 日至 6 月 3 日在西班牙巴伦西亚举行。 巴伦西亚，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 由来自 125 个国家的...